Reneo Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Hello, and welcome to this presentation with Reneo Pharmaceuticals. I'm pleased to be joined by Greg Flesher, President and CEO, who is going to give us a presentation before I'll ask him some questions at the end. Thanks so much for being with us, Greg.
Joe, thank you for inviting us to present at your conference, and it's good to see you again. Thank you.
So thank, everyone. Good afternoon and thanks for joining the call today. For those unfamiliar with Reneo Pharmaceuticals, we are an emerging orphan disease company. We are very far along in clinical development. We're going to talk today about our lead compound called mavodelpar, previously called REN001. And we're going to talk about how this drug plays or could play a key role in the treatment of patients with mitochondrial diseases.
I would encourage everyone we do file all of our risk factors and through the SEC and through our website. I really encourage everyone to take the time to read the risk factors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
